

The use of Endoret PRGF in ocular surface diseases


Endoret® PRGF® (plasma rich in growth factors) is a Health Canada licensed technology for obtaining autologous proteins from the patient's own blood.

Case 1: Sjögren – related Dry Eye Disease

Case 1:	Current Treatment: Without improvement to baseline symptoms	Baseline symptoms:
<ul style="list-style-type: none"> • 67-year-old female • Sjögren's syndrome with DED • previous history of a sterile corneal ulcer • previously unresponsive to autologous serum 	<ul style="list-style-type: none"> • non-preserved artificial tears • non-preserved dexamethasone • Restasis • lubricant ointment • Loteprednol ointment • sublingual 4% pilocarpine 	<ul style="list-style-type: none"> • Constant irritation • Redness • Dryness

Assessment Type	Baseline Visit	FUP Visit September 21, 2021 Added Endoret PRGF® August 21, 2021
CDEA (Canadian Dry Eye Assessment)	24/48	10/48
Difficulty driving	half of the time	None of the time
Vision	Fluctuating, impaired to read, drive, and use computer	Stable
TBUT	1 second	Improved
TMH (tear meniscus height)	Negligible	Improved
Corneal staining	Diffuse, grade 3	Improved
Other observations	Excessive mucus secretion	Considerably less

Case series report: **The use of Endoret PRGF in Ocular Surface Diseases**
By **Dr. Rookaya Mather, MD, FRCSC, FACS**



Chronic, unresponsive cases of DED likely require multiple therapeutic combinations and cycles of interventions, including Endoret PRGF.

Clinical consideration:

Advancing therapy in SS-DED patients requires a proactive approach since these patients have a diminished capacity to heal from ocular surface stressors. **There is an obvious need for a more individualized and specific treatment plan.**


Controlling inflammation, growth factor therapy and tear retention are important measures in preventing severe dryness cycles and decompensation of the ocular surface. **Chronic, unresponsive cases**

of DED likely require multiple therapeutic combinations and cycles of interventions, including Endoret PRGF. Adjunctive therapies such as Endoret PRGF drops in scleral lenses, punctal occlusion or new agents such as inhaled tear stimulants (Tyrvaya) may enhance the effectiveness of treatment. Taking time with patients to discuss the next steps in management provides patients with hope and time for logistical planning, such as financial and insurance considerations.

To listen to

Unlocking Hope For Refractory Sjögren's Syndrome Patients

by **Dr. Rookaya Mather, MD, FRCSC, FACS**



Dr. Mather's **White Paper**



Dr. Mather's **Webinar**

Case series report: **The use of Endoret PRGF in Ocular Surface Diseases**
By **Dr. Rookaya Mather, MD, FRCSC, FACS**